Theriva Biologics, Inc.
TOVX
$0.25
$0.014.52%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 13.51% | 7.46% | 1.88% | -32.73% | -30.34% |
| Total Depreciation and Amortization | -14.52% | -21.17% | -27.52% | -23.65% | -12.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 35.47% | 27.59% | 59.37% | 1,814.26% | 360.34% |
| Change in Net Operating Assets | -805.94% | -521.21% | -218.21% | -134.30% | -87.43% |
| Cash from Operations | 14.53% | 1.58% | 1.64% | -1.37% | 7.97% |
| Capital Expenditure | -3,400.00% | -3,400.00% | 38.60% | 91.40% | 99.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -3,400.00% | -3,400.00% | 38.60% | 91.40% | 99.48% |
| Total Debt Issued | -92.43% | -- | -- | -- | -- |
| Total Debt Repaid | 48.78% | -4.48% | -2.99% | 0.00% | -515.00% |
| Issuance of Common Stock | 255.42% | 214.02% | 24.24% | 447.40% | 150.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -147.94% | -- | 188.15% | 218.37% | 213.69% |
| Cash from Financing | 121.60% | 231.02% | 141.62% | 4,192.11% | 1,160.00% |
| Foreign Exchange rate Adjustments | -22,000.00% | 30.30% | -349.25% | -212.82% | 97.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 152.90% | 112.07% | 39.38% | 74.37% | 53.72% |